NEW YORK, Aug. 23, 2017 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of PetMed Express, Inc. ("PetMed" or the "Company") (NASDAQ: PETS). Such investors are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/pets.
The investigation concerns whether PetMed and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.
On August 23, 2017, Aurelius Value published an article alleging that PetMed targets opioid users with Google ads and other marketing techniques aimed at facilitating the abuse of opioids. Following this news, PetMed stock dropped as much as $6.26 per share, or 15.88%, during intraday trading on August 23, 2017.
If you are aware of any facts relating to this investigation, or purchased shares of PetMed, you can assist this investigation by visiting the firm's site: www.bgandg.com/pets. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.